Safety and efficacy outcomes in heavily and non-heavily pretreated patients with recurrent ovarian cancer (ROC) after single-agent trabectedin treatment: pooled analysis of phase II trials

被引：0
|
作者：
Kurzeder, C. [1 ]
Sehouli, J. [2 ]
Brugger, W. [3 ]
Zintl, P. [4 ]
De la Riba, M., I [4 ]
Kreienberg, R. [5 ]
机构：
[1] Kliniken Essen Mitte, Essen, Germany
[2] Charite, D-13353 Berlin, Germany
[3] Schwarzwald Baar Klinikum, Villingen Schwenningen, Germany
[4] PharmaMar SA, Colmenar Viejo, Spain
[5] Univ Ulm Klinikum, Ulm, Germany
来源：
ONKOLOGIE | 2011年 / 34卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：222 / 223
页数：2
相关论文
共 50 条
  • [31] Integrated safety summary of single-agent mirvetuximab soravtansine in patients with folate receptor α (FRα)-positive recurrent ovarian cancer: Phase 1 and 3 clinical trials.
    Moore, Kathleen N.
    Lorusso, Domenica
    Oaknin, Ana
    Oza, Amit M.
    Colombo, Nicoletta
    Van Gorp, Toon
    O'Malley, David M.
    Banerjee, Susana N.
    Murphy, Conleth G.
    Harter, Philipp
    Konecny, Gottfried E.
    Pautier, Patricia
    Method, Michael W.
    Wang, Jiuzhou
    Birrer, Michael J.
    Coleman, Robert L.
    Matulonis, Ursula A.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [32] Single-agent gemcitabine in pretreated patients with non-small-cell lung cancer: Results of an Argentinean multicentre phase II trial
    Van Kooten M.
    Traine G.
    Cinat G.
    Cazap E.
    Zori Comba A.
    Vicente H.
    Sena S.
    Rodriguez Nievas O.
    Orlando M.
    British Journal of Cancer, 1999, 81 (5) : 846 - 849
  • [33] Trabectedin as a Single-Agent Treatment of Advanced Breast Cancer After Anthracycline and Taxane Treatment: A Multicenter, Randomized, Phase II Study Comparing 2 Administration Regimens
    Goldstein, Lori J.
    Gurtler, Jayne
    Del Prete, Salvatore A.
    Tjulandin, Sergei
    Semiglazov, Vladimir F.
    Bayever, Eliel
    Michiels, Bart
    CLINICAL BREAST CANCER, 2014, 14 (06) : 396 - 404
  • [34] Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial
    Sorio, Roberto
    Roemer-Becuwe, Celia
    Hilpert, Felix
    Gibbs, Emma
    Garcia, Yolanda
    Kaern, Janne
    Huizing, Manon
    Witteveen, Petronella
    Zagouri, Flora
    Coeffic, David
    Luck, Hans-Joachim
    Gonzalez-Martin, Antonio
    Kristensen, Gunnar
    Levache, Charles-Briac
    Lee, Chee Khoon
    Gebski, Val
    Pujade-Lauraine, Eric
    GYNECOLOGIC ONCOLOGY, 2017, 144 (01) : 65 - 71
  • [35] Preliminary safety and efficacy results of camrelizumab in combination with apatinib and eribulin in heavily pretreated patients with advanced triple-negative breast cancer: A phase II trial
    Liu, Jieqiong
    Tian, Zhenluan
    Wang, Ying
    Lin, Ying
    Li, Hengyu
    CANCER RESEARCH, 2022, 82 (04)
  • [36] Single-Agent Trabectedin Versus Physician's Choice Chemotherapy in Patients With Recurrent Ovarian Cancer With BRCA-Mutated and/or BRCAness Phenotype: A Randomized Phase III Trial
    Lorusso, Domenica
    Raspagliesi, Francesco
    Ronzulli, Dominique
    Valabrega, Giorgio
    Colombo, Nicoletta
    Pisano, Carmela
    Cassani, Chiara
    Tognon, Germana
    Tamberi, Stefano
    Mangili, Giorgia
    Mammoliti, Serafina
    De Giorgi, Ugo
    Greco, Filippo
    Mosconi, Anna Maria
    Breda, Enrico
    Artioli, Grazia
    Andreetta, Claudia
    Casanova, Claudia
    Ceccherini, Rita
    Frassoldati, Antonio
    Salutari, Vanda
    Giolitto, Serena
    Scambia, Giovanni
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (13) : 1488 - 1498
  • [37] Efficacy and safety of single-agent pralatrexate for treatment of angioimmunoblastic T-cell lymphoma after failure of first line therapy: a pooled analysis
    Zhu, Jun
    Yeoh, Ee Min
    Maeda, Yoshinobu
    Tobinai, Kensei
    LEUKEMIA & LYMPHOMA, 2020, 61 (09) : 2145 - 2152
  • [38] Phase II trials of single-agent activity of gemcitabine in patients with advanced non-small cell lung cancer: An overview
    Shepherd, FA
    ANTI-CANCER DRUGS, 1995, 6 : 19 - 25
  • [39] Loncastuximab Tesirine Demonstrated Substantial Single-Agent Efficacy and Manageable Safety Profile in Heavily Pretreated Chinese Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
    Lin, Ningjing
    Sun, Xiuhua
    Zhou, Hui
    Zou, Liqun
    Zhou, Keshu
    Liu, Lihong
    Yang, Haiyan
    Hu, Kai
    Cai, Qingqing
    Liu, Yao
    Jin, Jie
    Zhang, Liling
    Li, Wenyu
    Guo, Ye
    Yang, Wei
    Luo, Feng
    Li, Yanyan
    Zhang, Mengqi
    Lu, Feinan
    Song, Yuqin
    Zhu, Jun
    BLOOD, 2023, 142
  • [40] Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2−metastatic breast cancer receiving single-agent chemotherapy—a comparison with MONARCH 1
    Hope S. Rugo
    Veronique Dieras
    Javier Cortes
    Debra Patt
    Hans Wildiers
    Joyce O’Shaughnessy
    Esther Zamora
    Denise A. Yardley
    Gebra Cuyun Carter
    Kristin M. Sheffield
    Li Li
    Valerie A. M. Andre
    Xiaohong I. Li
    Martin Frenzel
    Yu-Jing Huang
    Maura N. Dickler
    Sara M. Tolaney
    Breast Cancer Research and Treatment, 2020, 184 : 161 - 172
12345